Tiotropium vs Tiotropium + Formoterol in COPD

Phase 4, randomised, double-blind trial of formoterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline of the normalized area under the time curve (AUC) for FEV1 for the 0 hour to 4 hours post-morning dose. Started Sep 2005; status: completed.